-
![Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases](/abs-image/US/2016/11/22/US09499551B2/abs.jpg.150x150.jpg)
1.发明授权Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases 有权取代的吡咯并[2,3-b]吡啶用于治疗癌症或炎性疾病公开(公告)号：US09499551B2
公开(公告)日：2016-11-22
申请号：US14604016
申请日：2015-01-23
IPC分类号： C07D471/04 , C07D221/04 , C07D487/04
CPC分类号： C07D487/04 , C07D471/04
摘要： Disclosed herein are substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions useful in the treatment of TAK mediated diseases, such as cancer, having the structure of Formula (I): wherein R1, R2, R3, and R4 are as defined in the detailed description. Methods of modulation of TAK activity in a human or animal subject are also provided, providing therapeutic benefit to subjects with disease conditions, especially cancer.
-
公开(公告)号：US20160213653A1
公开(公告)日：2016-07-28
申请号：US15005627
申请日：2016-01-25
IPC分类号： A61K31/437 , C07D519/00 , A61K31/5377 , A61K31/506 , C07D471/04 , A61K45/06
CPC分类号： C07D519/00 , A61K45/06 , C07D471/04
摘要： Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
摘要翻译： 本文公开的是用于治疗具有式（I）结构的ITK介导的疾病例如炎症的杂环化合物和组合物：其中R1，R2和X如详细描述中所定义。 还提供了在人或动物受试者中抑制ITK活性的方法。
-
3.发明申请4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT 有权4-ALKOXY / ARALKOXY-5-取代的吡咯烷酮化合物作为TAK1抑制剂在疾病治疗中的作用公开(公告)号：US20150203499A1
公开(公告)日：2015-07-23
申请号：US14417518
申请日：2013-07-26
IPC分类号： C07D487/04 , A61K45/06 , A61K31/53 , A61K31/519
CPC分类号： C07D487/04 , A61K31/519 , A61K31/53 , A61K45/06
摘要： The present disclosure provides 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds, pharmaceutically acceptable salts, solvates and pharmaceutical compositions of compounds embraced by Formula (I), providing a therapeutic benefit to subjects with disease conditions, especially cancer, wherein R1 and R2 are as defined in the detailed description.
摘要翻译： 本公开提供了通过式（I）包含的化合物的4-烷氧基/芳烷氧基-5-取代的吡咯并嘧啶化合物，药学上可接受的盐，溶剂合物和药物组合物，为具有疾病状况，特别是癌症的受试者提供治疗益处，其中R1和 R2如在详细描述中所定义。
-
4.发明申请公开(公告)号：US20150210671A1
公开(公告)日：2015-07-30
申请号：US14603937
申请日：2015-01-23
IPC分类号： C07D401/14 , A61K31/444 , A61K31/497 , A61K45/06 , C07D405/14 , A61K31/5377 , C07D401/12 , A61K31/4427 , A61K31/4545 , A61K31/506
CPC分类号： C07D401/14 , A61K31/4427 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D405/14
摘要： Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
摘要翻译： 本文公开了芳族吡啶酮化合物和可用于治疗具有式（I）结构的ITK介导的疾病例如炎症的组合物：其中Ar，R 2，R 4，R 5，n和X如详细描述中所定义。 还提供了在人或动物受试者中抑制ITK活性的方法。
-
公开(公告)号：US09695200B2
公开(公告)日：2017-07-04
申请号：US15005627
申请日：2016-01-25
IPC分类号： A61K31/5377 , A61K31/506 , C07D471/04 , A61K45/06 , A61K31/437 , C07D519/00
CPC分类号： C07D519/00 , A61K45/06 , C07D471/04
摘要： Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
-
6.发明授权4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment 有权4-烷氧基/芳烷氧基-5-取代的吡咯并嘧啶化合物作为疾病治疗中的TAK1抑制剂公开(公告)号：US09505765B2
公开(公告)日：2016-11-29
申请号：US14417518
申请日：2013-07-26
IPC分类号： C07D487/04 , A61K31/519 , A61K45/06 , A61K31/53 , A61P35/00
CPC分类号： C07D487/04 , A61K31/519 , A61K31/53 , A61K45/06
摘要： 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds, pharmaceutically acceptable salts, solvates and pharmaceutical compositions of compounds embraced by Formula (I), provide a therapeutic benefit to subjects with disease conditions, especially cancer, wherein R1 and R2 are as defined in the detailed description.
-
公开(公告)号：US20150328227A1
公开(公告)日：2015-11-19
申请号：US14806148
申请日：2015-07-22
IPC分类号： A61K31/5377 , A61K45/06 , A61K31/506 , A61K31/497 , A61K31/4545 , A61K31/444
CPC分类号： A61K31/5377 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K45/06 , C07D401/12 , C07D401/14
摘要： Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
-
公开(公告)号：US09145393B2
公开(公告)日：2015-09-29
申请号：US14603937
申请日：2015-01-23
IPC分类号： C07D401/00 , C07D401/14 , A61K31/4545 , A61K31/444 , A61K31/497 , A61K31/506 , C07D405/14 , A61K31/5377 , C07D401/12 , A61K31/4427 , A61K45/06
CPC分类号： C07D401/14 , A61K31/4427 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D405/14
摘要： Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
摘要翻译： 本文公开了芳族吡啶酮化合物和可用于治疗具有式（I）结构的ITK介导的疾病例如炎症的组合物：其中Ar，R 2，R 4，R 5，n和X如详细描述中所定义。 还提供了在人或动物受试者中抑制ITK活性的方法。
-
9.发明申请SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES 有权用于治疗癌症或炎症疾病的替代吡咯啉和吡咯啉公开(公告)号：US20150210705A1
公开(公告)日：2015-07-30
申请号：US14604016
申请日：2015-01-23
IPC分类号： C07D487/04 , C07D471/04
CPC分类号： C07D487/04 , C07D471/04
摘要： Disclosed herein are substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions useful in the treatment of TAK mediated diseases, such as cancer, having the structure of Formula (I): wherein R1, R2, R3, and R4 are as defined in the detailed description. Methods of modulation of TAK activity in a human or animal subject are also provided, providing therapeutic benefit to subjects with disease conditions, especially cancer.
摘要翻译： 本文公开了取代的吡咯并吡啶和吡咯并吡嗪化合物和可用于治疗具有式（I）的结构的TAK介导的疾病如癌症的组合物：其中R1，R2，R3和R4如详细描述中所定义。 还提供了在人或动物受试者中调节TAK活性的方法，为患有疾病状况，特别是癌症的受试者提供治疗益处。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.041 秒)
